A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids

NCT02655224 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
65
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Takeda